Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma – Presentation of Full-Year report 2023

By HC Andersen Capital
Ascelia Pharma

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma on 9 February at 11:30 AM.

The topic for this event is the Q4 and Full-Year report and major events during the last quarter in 2023. In Q4, Ascelia Pharma announced a re-start of the Imaging Reading Phase and re-confirmed Phase 3 SPARKLE results by May 2024. Ascelia Pharma will update the investor community on the roll-out strategy for Orviglance to the market.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia Pharma has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 12/1/2024 09.03 AM.

Recent videos

HCA Morgenbørs 08/12 - Små fald i futures og fokus på Gubra, Genmab og Lundbeck
08.12.2025, 09.24 Genmab
AKTIER MED FRIIS - UGE 49 2025
05.12.2025, 12.00
HCA Morgenbørs 05/12 - Overvejende positive futures-markeder hvor kun Japan er i minus
05.12.2025, 09.20 GreenMobility
GreenMobility: What is the investment case in driverless cars
05.12.2025, 08.00 GreenMobility
UPM and Sappi are planning a joint venture in graphic papers
04.12.2025, 13.00 UPM-Kymmene
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.